Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast Cancer

An Exploratory Prospective Single-Arm Study of Trastuzumab Rezetecan Combined With Toripalimab and Endocrine Therapy as Neoadjuvant Treatment in Patients With Stage II-III HR-Positive, HER2-Low Primary Breast Cancer

This is a single-arm, prospective exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of trastuzumab rezetecan (SHR-A1811) combined with toripalimab and endocrine therapy as neoadjuvant treatment for patients with stage II-III HR-positive, HER2-low primary breast cancer.

Eligible participants will receive the combination neoadjuvant regimen before surgery. The primary endpoint is pathological complete response (pCR, ypT0/is ypN0) rate after surgery. Secondary endpoints include objective response rate (ORR), residual cancer burden (RCB), event-free survival (EFS), overall survival (OS), and safety.

A total of 30 participants will be enrolled. The recruitment period will last for 12 months. All enrolled subjects will receive study treatment and follow-up according to the study protocol.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Tianjin, China, 300060
        • Recruiting
        • Tianjin Medical University Cancer Institute and Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  1. Aged ≥18 and ≤70 years old.
  2. Histopathologically confirmed invasive breast cancer; no prior systemic anti-tumor therapy for breast cancer.
  3. Histopathologically confirmed HR-positive (ER >1%) and HER2-low breast cancer. HER2-low is defined as IHC 1+ or IHC 2+ with ISH-negative.
  4. Ki-67 proliferation index ≥30%.
  5. Stage II-III breast cancer per the 8th edition AJCC TNM staging criteria (cT2 N1-2 M0, or T3-4 N0-2 cM0).
  6. At least one measurable target lesion according to RECIST Version 1.1.
  7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
  8. Female participants may be pre-menopausal, peri-menopausal or post-menopausal. Post-menopause is defined according to CSCO Breast Cancer Guidelines as any one of the following:

Bilateral oophorectomy;

  1. Age ≥ 60 years;
  2. Age < 60 years with spontaneous amenorrhea for ≥12 months; no chemotherapy, tamoxifen, toremifene or ovarian function suppression in the past 12 months, and post-menopausal levels of FSH and estradiol;
  3. Age < 60 years receiving tamoxifen or toremifene, with post-menopausal FSH and estradiol levels documented on two consecutive tests.

9、Adequate organ function (no blood product or growth-factor-supported correction within 14 days prior to first study drug administration):

  1. Hematologic function: Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; platelets ≥ 100 × 10⁹/L; hemoglobin ≥ 90 g/L.
  2. Hepatic and renal function: Albumin ≥ 3.0 g/dL; total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; blood urea nitrogen and serum creatinine ≤ 1.5 × ULN OR creatinine clearance ≥ 60 mL/min (calculated by Cockcroft-Gault formula).
  3. Coagulation: Prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.
  4. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% assessed by echocardiogram (ECHO).
  5. Electrocardiogram: QTcF (Fridericia-corrected QT interval) ≤ 470 ms for female subjects.

10、For pre-menopausal women of child-bearing potential: serum pregnancy test negative within 7 days before initiation of study treatment; non-lactating. All enrolled female participants must use adequate barrier contraception throughout treatment and for 6 months after completion of study treatment.

11、Voluntarily agrees to participate, provides written informed consent, demonstrates good compliance and is willing to complete all study-related visits and procedures.

Exclusion Criteria:

  1. Breast cancer without histopathological confirmation.
  2. Bilateral breast cancer, inflammatory breast cancer or occult breast cancer.
  3. Prior anti-neoplastic therapy of any modality (chemotherapy, radiotherapy, targeted therapy, endocrine therapy, etc.). Definitive radiotherapy received within 4 weeks before first study drug dose, or palliative radiotherapy received within 2 weeks before first study drug dose.
  4. Concurrent receipt of any other anti-tumor therapy.
  5. History of other malignancies within the past 5 years, except for cured basal-cell skin carcinoma and carcinoma in situ of cervix.
  6. Participation in another investigational-drug clinical trial within 4 weeks prior to enrollment.
  7. Received immunosuppressive agents or systemic corticosteroids for immunosuppressive purposes (>10 mg/day prednisone equivalent) within 2 weeks before first study drug administration; nasal or inhaled corticosteroids are permitted.
  8. Administration of live or attenuated vaccines within 4 weeks prior to first study drug dose.
  9. Major surgery unrelated to breast cancer within 4 weeks before first study drug dose, or incomplete recovery from such surgery.
  10. Active autoimmune disease, or history of autoimmune disease prone to relapse (including but not limited to autoimmune hepatitis, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism; hypothyroidism controlled solely by hormone-replacement therapy is allowed). Subjects with skin disorders not requiring systemic therapy (vitiligo, psoriasis, alopecia), insulin-controlled type 1 diabetes, or childhood-onset asthma fully resolved without adult-time intervention may be enrolled. Asthma requiring bronchodilator intervention is excluded.
  11. History of immunodeficiency, including HIV-positive status, other acquired or congenital immunodeficiency, or history of organ transplantation.
  12. Uncontrolled or clinically significant cardiovascular-cerebrovascular disease. Any of the following occurring within 6 months prior to first dose: NYHA class III-IV congestive heart failure, myocardial infarction, cerebral infarction (lacunar infarction excluded), pulmonary embolism, unstable angina; arrhythmias requiring treatment at screening; primary cardiomyopathy (dilated, hypertrophic, arrhythmogenic right-ventricular, restrictive or unclassified cardiomyopathy); clinically significant history of QTc prolongation; second-degree type-II or third-degree atrioventricular block; female QTcF > 470 ms; atrial fibrillation (EHRA grade ≥ 2b); uncontrolled hypertension judged by investigator to make subject ineligible.
  13. Known or suspected interstitial pneumonia; moderate-to-severe pulmonary disease impairing respiratory function within 3 months before first dose that may confound detection/management of drug-related pulmonary toxicity, including idiopathic pulmonary fibrosis, organizing pneumonia / bronchiolitis obliterans, pulmonary embolism, severe asthma, severe COPD, obstructive/restrictive lung disease; autoimmune / connective-tissue / inflammatory diseases with pulmonary involvement (e.g. rheumatoid arthritis, Sjögren syndrome, sarcoidosis); prior total pneumonectomy.
  14. Active hepatitis B (HBsAg-positive with HBV-DNA ≥ 500 IU/mL), hepatitis C (HCV-antibody-positive with HCV-RNA above upper limit of normal), liver cirrhosis; severe infection requiring antibiotics, antiviral or antifungal therapy.
  15. Known inherited or acquired bleeding or thrombotic diathesis (e.g. hemophilia, coagulopathy).
  16. Known hypersensitivity or contraindications to study drugs or their excipients.
  17. Pregnant or lactating women; women of child-bearing potential with positive baseline serum pregnancy test; women of child-bearing potential unwilling to use effective contraception throughout the study period.
  18. Concomitant medical conditions that, in the investigator's judgment, would endanger subject safety or prevent completion of the study (including but not limited to uncontrolled severe hypertension, severe diabetes, active infection).
  19. Documented history of neurological or psychiatric disorders including epilepsy or dementia; or any other condition rendering the subject unsuitable for the study in the investigator's opinion.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Trastuzumab Rezetecan plus Toripalimab and Endocrine Therapy Neoadjuvant Treatment

Patients receive 6 cycles of neoadjuvant trastuzumab rezetecan (4.8 mg/kg IV Q3W) plus toripalimab (240 mg IV Q3W) plus daily endocrine therapy (SERM/AI ± OFS; OFS for pre/perimenopausal women), followed by surgery.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pathological Complete Response Rate (pCR, ypT0/isN0)
Time Frame: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

Percentage of patients achieving pathological complete response (pCR, defined as ypT0/isN0) in breast and axillary lymph nodes after neoadjuvant therapy, assessed by central pathology review after surgery

At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR)
Time Frame: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

Percentage of patients with confirmed objective response (CR or PR) assessed by investigator according to RECIST criteria.

At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
Residual Cancer Burden (RCB)
Time Frame: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).

RCB class and continuous RCB score determined from surgical specimens after neoadjuvant treatment.

At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
Event-Free Survival (EFS)
Time Frame: Up to 3 years after surgery

Time from enrollment to first occurrence of invasive breast cancer recurrence, distant metastasis, second primary malignancy, or death from any cause, whichever comes first.

Up to 3 years after surgery
Overall Survival (OS)
Time Frame: Up to 5 years after surgery

Time from enrollment to death from any cause.

Up to 5 years after surgery
Safety
Time Frame: From start of study treatment up to 30 days after last dose of study drugs

Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) graded per CTCAE.

From start of study treatment up to 30 days after last dose of study drugs

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immune biomarkers (sTIL, PD-L1, etc.)
Time Frame: Baseline and at surgery

Assessment of immune biomarkers including stromal tumor-infiltrating lymphocytes (sTIL) and PD-L1 expression in baseline tumor samples and post-treatment surgical specimens.

Baseline and at surgery
Ki-67 expression
Time Frame: Baseline and at surgery

Change in Ki-67 proliferation index between baseline biopsy and surgical specimens after neoadjuvant therapy.

Baseline and at surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 1, 2026

Primary Completion (Estimated)

May 31, 2028

Study Completion (Estimated)

May 31, 2029

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 17, 2026

First Posted (Actual)

November 19, 2026

Study Record Updates

Last Update Posted (Actual)

November 19, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • E20261415

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe